SAN DIEGO, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that Andy Rasdal, Chief Executive Officer and Bill Plovanic, Chief Financial Officer of Obalon will present at two upcoming investor conferences:
- Stifel 2016 Healthcare Conference
Wednesday, November 16, 2016 at 8:00 a.m. Eastern Time
Lotte New York Palace Hotel, New York, NY
Webcast Available at: http://wsw.com/webcast/stifel5/obln
- Canaccord Genuity Medical Technologies & Diagnostics Forum
Thursday, November 17, 2016 at 4:00 p.m. Eastern Time
Westin Grand Central, New York, NY
Webcast Available at: http://wsw.com/webcast/canaccord24/obln
Live audio webcasts of the presentations can be accessed at the links above. Replays of the webcasts will be available for 90 days following each presentation.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN), is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 firstname.lastname@example.org Media Contact: Megan Driscoll EvolveMKD Office Phone: +1 646 517 1565 email@example.com
Source:Obalon Therapeutics, Inc.